Skip to Content

Rule

Medicare Program; End-Stage Renal Disease Quality Incentive Program; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure, and Appeals Process for Breach of Contract Actions; Correction

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 94268

AGENCY:

Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION:

Final rule; correction.

SUMMARY:

This document corrects technical and typographical errors that appeared in the final rule published in the Federal Register on November 4, 2016, entitled “Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model.”

DATES:

This correction is effective on January 1, 2017.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Julia Howard, (410) 786-8645, for issues related to DMEPOS CBP and bid surety bonds, state licensure, and the appeals process for breach of DMEPOS CBP contract actions. Stephanie Frilling, (410) 786-4507, for issues related to the ESRD QIP.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Background

In FR Doc. 2016-26152 of November 4, 2016 (81 FR 77834) (hereinafter referred to as the CY 2017 ESRD PPS final rule) there are technical and typographical errors that are discussed in the “Summary of Errors,” and further identified and corrected in the “Correction of Errors” section below. The provisions in this correction notice are effective as if they had been included in the CY 2017 ESRD PPS final rule published in the Federal Register on November 4, 2016.

II. Summary of Errors

On page 77874, we inadvertently made technical errors with respect to the calculation of the performance standard values in Table 2, “Improvement of Performance Standards Over Time.”

On page 77886, we inadvertently made technical errors with respect to the calculation based on the most recently available data of the Achievement Threshold and Performance Standard values that apply to the Kt/V Composite, Standardized Transfusion Ratio and Hypercalcemia measures, and the calculation based on the most recently available data of the Achievement Threshold, Benchmark and Performance Standard values that apply to the ICH CAHPS measure in Table 6, “Finalized Numerical Values for the Performance Standards for the PY 2019 ESRD QIP Clinical Measures Using the Most Recently Available Data.” We also inadvertently included values for the Achievement Threshold, Benchmark and Performance Standard for the Standardized Hospitalization Ratio Clinical Measure, which is not a measure that we have adopted for the PY 2019 program.

On page 77897, we inadvertently included values for the Standardized Hospitalization Ratio Clinical Measure, which is not a finalized PY 2019 ESRD QIP measure, in Table 12, “PY 2020 Clinical Measure Including Facilities With at Least 11 Eligible Patients Per Measure.”

On page 77932 we made a technical error in our response to the first comment under “1. Bid Surety Bond Requirement”. In our response, we stated “While we acknowledge that there will be a number of entities that are required to make large expenditures in order to obtain a bid surety bond for each CBA in which they are submitting a bid, we anticipate that this revision on the bid surety bond amount from $100,000 to $50,000 will reduce that overall burden on all suppliers.” We inadvertently included the term “suppliers” at the end of the sentence but the term should read “bidders.”

On page 77933 in our response to the comment on why the bid surety bond was only required until January 1, 2019, we inadvertently included a “1” in the reference to the round of competition in 2019 in which the bid surety bond requirement commences. The reference should read “Round 2019” and not “Round 1 2019.”

At the top of page 77934 in our discussion on “Appeals Process for a DMEPOS Competitive Bidding Breach of Contract Action” we repeated a typographical error from the proposed rule (81 FR 42849) by stating that we proposed removing “§ 414.423(g)(2)(i)” from the regulation. The correct citation in this discussion should read “§ 414.422(g)(2)(i)”, consistent with the proposal to remove corrective action plan from the list of actions for a breach of contract in the regulation, as described in the preamble and regulation text of the proposed and final rules (81 FR 42849, 42878, and 81 FR 77934, 77967).

III. Waiver of Proposed Rulemaking, 60-Day Comment Period, and Delay of Effective Date

Under 5 U.S.C. 553(b) of the Administrative Procedure Act (APA), the agency is required to publish a notice of the proposed rule in the Federal Register before the provisions of a rule take effect. Similarly, section 1871(b)(1) of the Act requires the Secretary to provide notice of the proposed rule in the Federal Register and provide a period of not less than 60 days for public comment. In addition, section 553(d) of the APA, and section 1871(e)(1)(B)(i) of the Act mandate a 30-day delay in effective date after issuance or publication of a rule. Sections 553(b)(B) and 553(d)(3) of the APA provide for exceptions from the notice and comment and delay in effective date. APA requirements; in cases in which these exceptions apply, sections 1871(b)(2)(C) and 1871(e)(1)(B)(ii) of the Act provide exceptions from the notice and 60-day comment period and delay in effective date requirements as well. Section 553(b)(B) of the APA and section 1871(b)(2)(C) of the Act authorize an agency to dispense with normal rulemaking requirements for good cause if the agency makes a finding that the notice and comment process are impracticable, unnecessary, or contrary to the public interest. In addition, both section 553(d)(3) of the APA and section 1871(e)(1)(B)(ii) of the Act allow the agency to avoid the 30-day delay in effective date where such delay is contrary to the public interest and an agency includes a statement of support.

In our view, this correcting document does not constitute rulemaking that would be subject to these requirements. This correcting document is simply correcting technical errors in the preamble and does not make substantive changes to the policies or payment methodologies that were adopted in the final rule, and therefore, it is unnecessary to follow the notice and comment procedure in this instance.Start Printed Page 94269

Even if this were a rulemaking to which the notice and comment and delayed effective date requirements applied, we find that there is good cause to waive such requirements. Undertaking further notice and comment procedures to incorporate the corrections in this document into the CY 2017 ESRD PPS final rule or delaying the effective date would be contrary to the public interest because it is in the public's interest for dialysis facilities to receive appropriate payments in as timely a manner as possible, and to ensure that the CY 2017 ESRD PPS final rule accurately reflects our policies as of the date they take effect and are applicable. Further, such procedures would be unnecessary, because we are not altering the payment methodologies or policies. For these reasons, we believe we have good cause to waive the notice and comment and effective date requirements.

IV. Correction of Errors

In FR Doc. 2016-26152 of November 4, 2016 (81 FR 77834), we make the following corrections:

1. On page 77874, Table 2 is corrected to read as follows:

Table 2—Improvement of Performance Standards Over Time

MeasurePY 2015PY 2016PY 2017PY 2018PY 2019
Hemoglobin >12 g/dL1%0%
Vascular Access Type:
% Fistula60%62.3%64.46%65.94%65.93%
% Catheter13%10.6%9.92%8.80%9.19%
Kt/V:
Adult Hemodialysis93%93.4%96.89%97.24%
Adult Peritoneal Dialysis84%85.7%87.10%89.47%
Pediatric Hemodialysis93%93%94.44%93.94%
Pediatric Peritoneal Dialysis72.60%
Hypercalcemia1.70%1.30%1.19%1.85%
NHSN Bloodstream Infection SIR0.8610.797
Standardized Readmission Ratio0.9980.9980.998
Standardized Transfusion Ratio0.9230.894

2. On page 77886, Table 6 is corrected to read as follows:

Table 6—Finalized Numerical Values for the Performance Standards for the PY 2019 ESRD QIP Clinical Measures Using the Most Recently Available Data

MeasureAchievement thresholdBenchmarkPerformance standard
Vascular Access Type:
%Fistula53.66%79.62%65.93%
%Catheter17.20%2.95%9.19%
Kt/V Composite86.99%97.74%93.08%
Hypercalcemia4.24%0.32%1.85%
Standardized Transfusion Ratio1.4880.4210.901
Standardized Readmission Ratio1.2890.6240.998
NHSN Bloodstream Infection1.73800.797
ICH CAHPS: Nephrologists' Communication and Caring56.41%77.06%65.89%
ICH CAHPS: Quality of Dialysis Center Care and Operations52.88%71.21%60.75%
ICH CAHPS: Providing Information to Patients72.09%85.55%78.59%
ICH CAHPS: Overall Rating of Nephrologists49.33%76.57%62.22%
ICH CAHPS: Overall Rating of Dialysis Center Staff48.84%77.42%62.26%
ICH CAHPS: Overall Rating of the Dialysis Facility51.18%80.58%65.13%
Data Sources: VAT measures: 2015 Medicare claims; SRR, STrR: 2015 Medicare claims; Kt/V: 2015 Medicare claims and 2015 CROWNWEB; Hypercalcemia: 2015 CROWNWeb; NHSN: CDC; CAHPS: 2015 ICH CAHPS surveys.
Start Printed Page 94270

3. On page 77897, Table 12 is corrected to read as follows:

Table 12—PY 2020 Clinical Measures Including Facilities With at Least 11 Eligible Patients per Measure

MeasureN75th/25th Percentile90th/10th PercentileStd errorStatistically Indistin- guishableTruncated meanTruncated SDTCVTCV's 0.10
Kt/V Delivered Dose above minimum621096.098.00.093No92.54.200.05Yes.
Fistula Use590673.279.60.148No65.78.880.14No.
Catheter Use59215.432.890.093No1 90.15.16<0.01Yes.
Serum Calcium >10.262570.910.320.049No1 97.81.48<0.01Yes.
NHSN—SIR57810.410.000.011No0.9630.57<0.01Yes.
SRR57390.820.640.004No0.9950.21<0.01Yes.
STrR56500.640.430.008No0.9650.37<0.01Yes.
ICH CAHPS:
Nephrologists communication and caring334971.877.10.159No65.77.110.11No.
Quality of dialysis center care and operations334966.271.20.134No60.96.200.10No.
Providing information to patients334982.485.60.101No78.44.610.06Yes.
Rating of Nephrologist334969.976.60.204No62.09.290.15No.
Rating of dialysis facility staff334970.977.40.215No62.09.920.16No.
Rating of dialysis center334973.880.60.221No64.810.180.16No.
1 Truncated mean for percentage is reversed (100 percent−truncated mean) for measures where lower score = better performance.

4. On page 77932, third column, line 17, the word “suppliers” is corrected to read as “bidders”.

5. On page 77933, first column, line 30, remove the number “1” before “2019”.

6. On page 77934, first column, line 3, the citation “§ 414.423(g)(2)(i)” is corrected to read “§ 414.422(g)(2)(i)”.

Start Signature

Dated: December 19, 2016.

Madhura Valverde,

Executive Secretary to the Department, Department of Health and Human Services.

End Signature End Supplemental Information

[FR Doc. 2016-31019 Filed 12-22-16; 8:45 am]

BILLING CODE 4120-01-P